Hello! You're looking at a policy document report on Overton

We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work. Are you interested in seeing what information we have to offer? Request a free trial to our platform.

If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.

Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

Flag for USA Centers for Disease Control and Prevention (CDC) on March 8th 2000
A previously published report provided guidelines for managing the pharmacologic interactions that can result when patientsreceive protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis (TB). Protease inhibitors and NNRTIs are antiretroviral agents that are substrates that may inhibit or induce cytochrome P-450 isoenzymes (CYP450). Rifamycins are antituberculosis agents that induce CYP450 and may decrease substantially blood levels of the antiretroviral drugs. The pharmacologic interactions are called "drug-drug" because, in addition to the effect rifamycins have on protease inhibitors and NNRTIs, the antiretroviral agents may affect the blood levels of rifamycins. This notice presents updated data pertaining to drug-drug interactions between these agents and recommendations for their use from a group of CDC scientists and outside expert consultants.

Topics in this document

Related SDGs

Citations

Cited by 15 other policy documents (7 of them are from other policy sources)